Hutchmed China Limited Adr (HCM)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Hutchmed China Limited Adr Stock (HCM) Company Profile

Hutchmed China Limited Adr

Healthcare (1161)

Nächster Verdiensttermin

Neueste SEC-Einreichungen

HCM's Discussions on Twitter

Vergleichen Sie HCM mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
HCM Hutchmed China Limited Adr	17.68	2.83B	630.20M	37.73M	-17.44M	0.20
ZTS Zoetis Inc	151.19	68.05B	9.29B	2.52B	2.28B	5.57
TAK Takeda Pharmaceutical Co Adr	14.55	46.58B	30.08B	710.16M	4.45B	0.2182
HLN Haleon Plc Adr	9.65	43.71B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	16.29	18.40B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	297.89	13.23B	2.99B	1.21B	1.13B	25.06

Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-05-13	Herabstufung	HSBC Securities	Buy → Hold
2023-11-24	Hochstufung	Deutsche Bank	Hold → Buy
2022-05-04	Herabstufung	Deutsche Bank	Buy → Hold
2021-09-22	Herabstufung	Goldman	Buy → Neutral
2021-08-03	Eingeleitet	Jefferies	Buy
2020-10-02	Eingeleitet	Deutsche Bank	Buy
2020-03-13	Eingeleitet	Cantor Fitzgerald	Overweight
2020-02-20	Eingeleitet	Goldman	Buy
2019-11-19	Eingeleitet	CLSA	Buy
2019-10-23	Bestätigt	BofA/Merrill	Buy
2019-07-05	Eingeleitet	Macquarie	Outperform

Alle ansehen

Hutchmed China Limited Adr Aktie (HCM) Neueste Nachrichten

Finanzdaten der Hutchmed China Limited Adr-Aktie (HCM)

Hutchmed China Limited Adr (HCM)

Hutchmed China Limited Adr Stock (HCM) Company Profile

Vergleichen Sie HCM mit anderen Aktien

Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades

Hutchmed China Limited Adr Aktie (HCM) Neueste Nachrichten

Carvana Co. (NYSE:CVNA) Major Shareholder Sells $35,236,000.00 in Stock - Defense World

Vail Resorts, Inc. (NYSE:MTN) Stake Boosted by Crossmark Global Holdings Inc. - Defense World

6,121 Shares in John Hancock Multifactor Large Cap ETF (NYSEARCA:JHML) Bought by Crossmark Global Holdings Inc. - Defense World

Concurrent Investment Advisors LLC Acquires New Holdings in ADMA Biologics Inc (NASDAQ:ADMA) - Defense World

Crossmark Global Holdings Inc. Has $356,000 Holdings in Nordson Corporation (NASDAQ:NDSN) - Defense World

Buenaventura Mining (NYSE:BVN) vs. Hochschild Mining (OTCMKTS:HCHDF) Head-To-Head Review - Defense World

Coinbase Global, Inc. (NASDAQ:COIN) Given Average Rating of “Moderate Buy” by Brokerages - Defense World

HUTCHMED (NASDAQ:HCM) Rating Increased to Strong-Buy at Wall Street Zen - Defense World

Rhumbline Advisers Has $69,000 Position in Full Truck Alliance Co. Ltd. Sponsored ADR (NYSE:YMM) - Defense World

HUTCHMED (China) Limited (NASDAQ:HCM) Shares Bought by Bank of America Corp DE - Defense World

Public Employees Retirement System of Ohio Has $39,000 Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Two Sigma Investments LP Sells 12,471 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Wall Street Analysts See a 68.3% Upside in HUTCHMED (HCM): Can the Stock Really Move This High? - sharewise

Market news - investments.halifax.co.uk

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma - The Manila Times

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma - Yahoo Finance

HUTCHMED and Innovent Jointly Announce NDA Acceptance in - GlobeNewswire

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma - GlobeNewswire Inc.

Northern Trust Corp Sells 10,700 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Millennium Management LLC Sells 100,366 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

D. E. Shaw & Co. Inc. Trims Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

BNP Paribas Financial Markets Trims Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Jane Street Group LLC Grows Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Barclays PLC Purchases 2,255 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Manila Times

UPDATEInternational companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025 - The Globe and Mail

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025 - Yahoo Finance

International companies to host live webcasts at Deutsche - GlobeNewswire

About Us - FinancialContent

HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial - Barchart.com

Marshall Wace LLP Acquires New Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - The AM Reporter

CN Reportedly Directs Pharmas, Hospitals to Study Feasibility of Substituting US Imported Products - AASTOCKS.com

RCSHutchmed China LtdHUTCHMEDData to be Presented at AACR 2025 - TradingView

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China - Yahoo Finance

HUTCHMEDOncology portfolio growth expected to continue - Research Tree

HUTCHMED (China) Limited (NASDAQ:HCM) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - Defense World

Richard Li Invited to Attend China Development Forum, Pictured with Li Qiang and Others - AASTOCKS.com

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees - GlobeNewswire

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 - GlobeNewswire

Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China - The Manila Times

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 - GlobeNewswire

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023 - AsiaOne

HUTCHMED (HCM) Upgraded to Buy: Here's Why - Yahoo Finance

Wall Street Analysts Believe HUTCHMED (HCM) Could Rally 72.83%: Here's is How to Trade - Yahoo Finance

CN NMPA Guides Pharmas, Research Institutes to Enlarge R&D of Innovative Drugs, High-Quality Generic Drugs - AASTOCKS.com

ABC Arbitrage SA Buys New Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - MarketBeat

Sea Limited Sponsored ADR (SE) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance

Crossmark Global Holdings Inc. Increases Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

CN Healthcare Fund Breaks even w/ Slim Surplus in 2024 - AASTOCKS.com

HUTCHMED Announces NMPA Full Approval for - GlobeNewswire

Finanzdaten der Hutchmed China Limited Adr-Aktie (HCM)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie HCM